Template:Estrogen dosages for prostate cancer

From blackwiki
Jump to navigation Jump to search

Estrogen dosages for prostate cancer

Collapse
Route/form Estrogen Dosage Ref(s)
Oral Template:No selflink 1–2 mg 3x/day [1]
Template:No selflink 1.25–2.5 mg 3x/day [2][3]
Template:No selflink 0.15–3 mg/day [2][3][4]
Template:No selflink 1–2 mg 1x/week [5][3][6]
Template:No selflink 1–3 mg/day [2][7]
Template:No selflink 5 mg/day [8]
Template:No selflink 5 mg/day [8]
Template:No selflink 100–480 mg 1–3x/day [9][10][4]
Template:No selflink 12–48 mg/day [2][8][11][4]
Template:No selflink 900 mg/day [8]
Template:No selflink 140–1400 mg/day [12]
Transdermal patch Template:No selflink 2–6x 100 μg/day
Scrotal: 1x 100 μg/day
[13][14]
[15]
IM or SC injection Template:No selflink 1.66 mg 3x/week [16]
Template:No selflink 5 mg 1x/week [16]
Template:No selflink 10–40 mg 1x/1–2 weeks [17][18]
Template:No selflink 100 mg 1x/4 weeks [19][8]
Template:No selflink Alone: 160–320 mg 1x/4 weeks
With oral EE: 40–80 mg 1x/4 weeks
[20][19]
[21][8]
Template:No selflink 2–4 mg 2–3x/week [2][22]
IV injection Template:No selflink 300–1200 mg 1–7x/week [9][10][4]
Template:No selflink 240–450 mg/day [12][23]
Note: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. "ESTRACE TABLETS (estradiol tablets, USP)" (PDF). Warner Chilott. U.S. Food and Drug Administration.
  2. Jump up to: 2.0 2.1 2.2 2.3 2.4 Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1. Unknown parameter |name-list-style= ignored (help)
  3. Jump up to: 3.0 3.1 3.2 Oettel M (1999). "Estrogens and Antiestrogens in the Male". In Oettel M, Schillinger E (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. 135 / 2. Springer Science & Business Media. pp. 505–571. doi:10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. ISSN 0171-2004.
  4. Jump up to: 4.0 4.1 4.2 4.3 Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 51–. ISBN 978-3-642-86282-3.
  5. Höfling G, Heynemann H (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?" [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111.
  6. Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 March 2013). Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte. Springer-Verlag. pp. 91–. ISBN 978-3-642-60064-7.
  7. Lupulescu, Aurel (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6. Unknown parameter |name-list-style= ignored (help)
  8. Jump up to: 8.0 8.1 8.2 8.3 8.4 8.5 Günther H. Jacobi; Rudolf Hohenfellner (1 December 1982). Prostate Cancer. Williams & Wilkins. p. 223. ISBN 978-0-683-04354-9.
  9. Jump up to: 9.0 9.1 Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1.
  10. Jump up to: 10.0 10.1 von Bruchhausen, Franz; Dannhardt, Gerd; Ebel, Siegfried; Frahm, August W.; Hackenthal, Eberhard; Holzgrabe, Ulrike (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3. Unknown parameter |name-list-style= ignored (help)
  11. Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
  12. Jump up to: 12.0 12.1 Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs & Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781. S2CID 36725810.
  13. Ockrim J, Lalani JL, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nature Clinical Practice. Oncology. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433. S2CID 6847203.
  14. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". The Journal of Urology. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
  15. Re I, Asenjo G, Maximino G, Micheletti L (2005). "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer]. Revista Argentina de Urología (in Spanish). 70 (4): 231. ISSN 0325-2531.
  16. Jump up to: 16.0 16.1 "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
  17. "DELESTROGEN (estradiol valerate injection, USP)" (PDF). Par Pharmaceutical, Inc. U.S. Food and Drug Administration.
  18. Kohli M, Alikhan MA, Spencer HJ, Carter G (2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology. 22 (14_suppl): 4726. doi:10.1200/jco.2004.22.90140.4726. ISSN 0732-183X.
  19. Jump up to: 19.0 19.1 Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, et al. (February 2008). "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". British Journal of Cancer. 98 (4): 697–707. doi:10.1038/sj.bjc.6604230. PMC 2259178. PMID 18268497.
  20. "Estradurin Polyestradiol Phosphate". Pharmanovia. Archived from the original on 20 June 2016.
  21. Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–8. doi:10.1016/s0022-5347(01)66670-9. PMID 7500443.
  22. "Estrone suspension approval" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
  23. Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clinical Pharmacokinetics. 34 (2): 163–72. doi:10.2165/00003088-199834020-00004. PMID 9515186. S2CID 1943973.